| Dr Joseph A Gonzales Jr, MD | |
|
200 Henry Clay Avenue, New Orleans, LA 70118 | |
| (504) 896-9569 | |
| Not Available |
| Full Name | Dr Joseph A Gonzales Jr |
|---|---|
| Gender | Male |
| Speciality | Orthopedic Surgery |
| Experience | 24 Years |
| Location | 200 Henry Clay Avenue, New Orleans, Louisiana |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1003901539 | NPI | - | NPPES |
| 1502839 | Medicaid | LA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207X00000X | Orthopaedic Surgery | 201019 (Louisiana) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Children's Hospital | 8022207745 | 16 |
News Archive
Sanofi US (EURONEXT: SAN and NYSE: SNY) announced today data that showed lixisenatide, an investigational once-daily prandial glucagon-like peptide 1 (GLP-1) receptor agonist, decreased HbA1c by reducing PPG (postprandial glucose) daytime exposure when added to standard of care which includes basal insulin with or without oral anti-diabetic agents (OADs). Lixisenatide is for the treatment of adults with type 2 diabetes mellitus.
Results of a new study released this week in the June 2010 issue of The Journal of Pediatrics show that infants fed Enfamil LIPIL containing DHA and ARA during the first year of life experienced improved immune outcomes, including improved respiratory health, versus infants fed the same formulation without these beneficial lipids - and this health benefit was shown for the first three years of life.
Exelixis, Inc. today reported interim data from an ongoing phase 1 dose-escalation trial of XL147 (SAR245408) in combination with the EGFR inhibitor erlotinib in patients with advanced solid tumors.
Boehringer Ingelheim Pharmaceuticals, Inc. and the Duke Clinical Research Institute (DCRI) announced today the expansion of the Idiopathic Pulmonary Fibrosis – PROspective Outcomes (IPF-PRO) Registry, a patient registry developed to uncover insights into IPF, a rare and serious lung disease. The expansion will increase the study enrollment from 300 patients at 18 study sites to 1,500 patients at approximately 45 sites, creating the largest registry of newly diagnosed IPF patients.
› Verified 8 days ago
| Entity Name | Children's Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1306156138 PECOS PAC ID: 8022207745 Enrollment ID: O20110112000288 |
News Archive
Sanofi US (EURONEXT: SAN and NYSE: SNY) announced today data that showed lixisenatide, an investigational once-daily prandial glucagon-like peptide 1 (GLP-1) receptor agonist, decreased HbA1c by reducing PPG (postprandial glucose) daytime exposure when added to standard of care which includes basal insulin with or without oral anti-diabetic agents (OADs). Lixisenatide is for the treatment of adults with type 2 diabetes mellitus.
Results of a new study released this week in the June 2010 issue of The Journal of Pediatrics show that infants fed Enfamil LIPIL containing DHA and ARA during the first year of life experienced improved immune outcomes, including improved respiratory health, versus infants fed the same formulation without these beneficial lipids - and this health benefit was shown for the first three years of life.
Exelixis, Inc. today reported interim data from an ongoing phase 1 dose-escalation trial of XL147 (SAR245408) in combination with the EGFR inhibitor erlotinib in patients with advanced solid tumors.
Boehringer Ingelheim Pharmaceuticals, Inc. and the Duke Clinical Research Institute (DCRI) announced today the expansion of the Idiopathic Pulmonary Fibrosis – PROspective Outcomes (IPF-PRO) Registry, a patient registry developed to uncover insights into IPF, a rare and serious lung disease. The expansion will increase the study enrollment from 300 patients at 18 study sites to 1,500 patients at approximately 45 sites, creating the largest registry of newly diagnosed IPF patients.
› Verified 8 days ago
| Entity Name | North Oaks Medical Center, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1972630705 PECOS PAC ID: 2466629522 Enrollment ID: O20120117000359 |
News Archive
Sanofi US (EURONEXT: SAN and NYSE: SNY) announced today data that showed lixisenatide, an investigational once-daily prandial glucagon-like peptide 1 (GLP-1) receptor agonist, decreased HbA1c by reducing PPG (postprandial glucose) daytime exposure when added to standard of care which includes basal insulin with or without oral anti-diabetic agents (OADs). Lixisenatide is for the treatment of adults with type 2 diabetes mellitus.
Results of a new study released this week in the June 2010 issue of The Journal of Pediatrics show that infants fed Enfamil LIPIL containing DHA and ARA during the first year of life experienced improved immune outcomes, including improved respiratory health, versus infants fed the same formulation without these beneficial lipids - and this health benefit was shown for the first three years of life.
Exelixis, Inc. today reported interim data from an ongoing phase 1 dose-escalation trial of XL147 (SAR245408) in combination with the EGFR inhibitor erlotinib in patients with advanced solid tumors.
Boehringer Ingelheim Pharmaceuticals, Inc. and the Duke Clinical Research Institute (DCRI) announced today the expansion of the Idiopathic Pulmonary Fibrosis – PROspective Outcomes (IPF-PRO) Registry, a patient registry developed to uncover insights into IPF, a rare and serious lung disease. The expansion will increase the study enrollment from 300 patients at 18 study sites to 1,500 patients at approximately 45 sites, creating the largest registry of newly diagnosed IPF patients.
› Verified 8 days ago
| Entity Name | North Oaks Physician Group Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1427035211 PECOS PAC ID: 9133378870 Enrollment ID: O20121012000490 |
News Archive
Sanofi US (EURONEXT: SAN and NYSE: SNY) announced today data that showed lixisenatide, an investigational once-daily prandial glucagon-like peptide 1 (GLP-1) receptor agonist, decreased HbA1c by reducing PPG (postprandial glucose) daytime exposure when added to standard of care which includes basal insulin with or without oral anti-diabetic agents (OADs). Lixisenatide is for the treatment of adults with type 2 diabetes mellitus.
Results of a new study released this week in the June 2010 issue of The Journal of Pediatrics show that infants fed Enfamil LIPIL containing DHA and ARA during the first year of life experienced improved immune outcomes, including improved respiratory health, versus infants fed the same formulation without these beneficial lipids - and this health benefit was shown for the first three years of life.
Exelixis, Inc. today reported interim data from an ongoing phase 1 dose-escalation trial of XL147 (SAR245408) in combination with the EGFR inhibitor erlotinib in patients with advanced solid tumors.
Boehringer Ingelheim Pharmaceuticals, Inc. and the Duke Clinical Research Institute (DCRI) announced today the expansion of the Idiopathic Pulmonary Fibrosis – PROspective Outcomes (IPF-PRO) Registry, a patient registry developed to uncover insights into IPF, a rare and serious lung disease. The expansion will increase the study enrollment from 300 patients at 18 study sites to 1,500 patients at approximately 45 sites, creating the largest registry of newly diagnosed IPF patients.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Joseph A Gonzales Jr, MD 200 Henry Clay Avenue, New Orleans, LA 70118 Ph: (504) 896-9569 | Dr Joseph A Gonzales Jr, MD 200 Henry Clay Avenue, New Orleans, LA 70118 Ph: (504) 896-9569 |
News Archive
Sanofi US (EURONEXT: SAN and NYSE: SNY) announced today data that showed lixisenatide, an investigational once-daily prandial glucagon-like peptide 1 (GLP-1) receptor agonist, decreased HbA1c by reducing PPG (postprandial glucose) daytime exposure when added to standard of care which includes basal insulin with or without oral anti-diabetic agents (OADs). Lixisenatide is for the treatment of adults with type 2 diabetes mellitus.
Results of a new study released this week in the June 2010 issue of The Journal of Pediatrics show that infants fed Enfamil LIPIL containing DHA and ARA during the first year of life experienced improved immune outcomes, including improved respiratory health, versus infants fed the same formulation without these beneficial lipids - and this health benefit was shown for the first three years of life.
Exelixis, Inc. today reported interim data from an ongoing phase 1 dose-escalation trial of XL147 (SAR245408) in combination with the EGFR inhibitor erlotinib in patients with advanced solid tumors.
Boehringer Ingelheim Pharmaceuticals, Inc. and the Duke Clinical Research Institute (DCRI) announced today the expansion of the Idiopathic Pulmonary Fibrosis – PROspective Outcomes (IPF-PRO) Registry, a patient registry developed to uncover insights into IPF, a rare and serious lung disease. The expansion will increase the study enrollment from 300 patients at 18 study sites to 1,500 patients at approximately 45 sites, creating the largest registry of newly diagnosed IPF patients.
› Verified 8 days ago
Amit Kumar Sharma, MD Orthopedic Surgery Medicare: Not Enrolled in Medicare Practice Location: 200 Henry Clay Ave, Ste 4103 Children's Hospital, New Orleans, LA 70118 Phone: 504-896-9569 | |
Dr. Raoul Pedro Rodriguez, MD Orthopedic Surgery Medicare: Medicare Enrolled Practice Location: 1415 Tulane Ave, New Orleans, LA 70112 Phone: 504-988-2177 Fax: 504-988-4200 | |
Dr. Mark S Meyer, MD Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 1514 Jefferson Hwy, New Orleans, LA 70121 Phone: 504-842-4000 | |
Dr. Timothy John Skalak, M.D. Orthopedic Surgery Medicare: Medicare Enrolled Practice Location: 200 Henry Clay Ave, New Orleans, LA 70118 Phone: 504-899-3496 Fax: 504-896-9849 | |
Leslie Elaine Sisco, M.D. Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 1514 Jefferson Hwy, New Orleans, LA 70121 Phone: 504-842-3970 Fax: 504-842-6784 | |
Dr. Charles R Billings, M.D. Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 1415 Tulane Ave, New Orleans, LA 70112 Phone: 504-988-2177 Fax: 504-988-4200 |